Pei‐Pei Kung

机构：Pfizer (United States), The Fertilizer Institute · ORCID：0000-0002-9203-7374

发表论文 105 篇 · 总被引 3111 次 · h-index 21

代表论文

• Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer (2023 · Cell chemical biology · 被引 72)
• Identification of small-molecule protein–protein interaction inhibitors for NKG2D (2023 · Proceedings of the National Academy of Sciences · 被引 12)
• Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D) (2023 · Bioorganic & Medicinal Chemistry Letters · 被引 1)
• Abstract C029: PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancer (2025 · Molecular Cancer Therapeutics)
• Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide (2025 · Cancer Research)
• Supplementary Table 3 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer (2023)